In a retrospective, multicenter, and multinational study, the tolerability and safety of IL-17 and IL-23 inhibitors were evaluated in patients with psoriasis with newly diagnosed LTBI who received no treatment and in those who received chemoprophylaxis for TB. This evidence concerns the gene IL17A and tuberculosis.